Takeda Drug for Bowel Diseases Wins U.S. Panel’s Backing
This article is for subscribers only.
Takeda Pharmaceutical Co.’s treatment for the two most common inflammatory bowel diseases won the backing of U.S. advisers to the Food and Drug Administration.
The benefits of the medicine, vedolizumab, outweigh the potential risk of the drug causing a deadly brain disease, the advisory panel voted today. The FDA, which isn’t bound by the panel’s recommendation, may decide whether to approve the drug for ulcerative colitis by Feb. 18 and Crohn’s disease in June.